losartan has been researched along with Thrombosis in 16 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thus, the observed outcomes benefits favoring losartan may involve other possible mechanisms, including differential effects of losartan and atenolol on LVH regression, left atrial diameter, atrial fibrillation, brain natriuretic peptide, vascular structure, thrombus formation/platelet aggregation, serum uric acid, albuminuria, new-onset diabetes, and lipid metabolism." | 8.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| "A PubMed/MEDLINE search of English-language articles (1990 to February 2006) with the terms angiotensin II antagonists or AIIAs or angiotensin receptor blockers or losartan or atenolol or beta blocker and terms including, but not limited to, atherosclerosis, left ventricular hypertrophy, carotid artery hypertrophy, fatty streaks, atrial fibrillation, arrhythmias, endothelial function, myocyte hypertrophy, myocardial fibrosis, platelet aggregation, tissue factor, plasminogen activator inhibitor-1, PAI-1, anti-inflammatory, uric acid, or oxidative stress." | 8.83 | Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. ( Díez, J, 2006) |
| "We describe the reversal of losartan-induced oligohydramnios at 27 weeks of gestation with subsequent development of fetal thrombosis and possible mechanism of action for this extremely rare in utero complication." | 7.73 | In utero losartan withdrawal and subsequent development of fetal inferior vena cava thrombosis. ( Bakkum, JN; Brost, BC; Johansen, KL; Johnston, BW; Watson, WJ, 2006) |
| " Thus, the observed outcomes benefits favoring losartan may involve other possible mechanisms, including differential effects of losartan and atenolol on LVH regression, left atrial diameter, atrial fibrillation, brain natriuretic peptide, vascular structure, thrombus formation/platelet aggregation, serum uric acid, albuminuria, new-onset diabetes, and lipid metabolism." | 4.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| "A PubMed/MEDLINE search of English-language articles (1990 to February 2006) with the terms angiotensin II antagonists or AIIAs or angiotensin receptor blockers or losartan or atenolol or beta blocker and terms including, but not limited to, atherosclerosis, left ventricular hypertrophy, carotid artery hypertrophy, fatty streaks, atrial fibrillation, arrhythmias, endothelial function, myocyte hypertrophy, myocardial fibrosis, platelet aggregation, tissue factor, plasminogen activator inhibitor-1, PAI-1, anti-inflammatory, uric acid, or oxidative stress." | 4.83 | Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. ( Díez, J, 2006) |
| "We describe the reversal of losartan-induced oligohydramnios at 27 weeks of gestation with subsequent development of fetal thrombosis and possible mechanism of action for this extremely rare in utero complication." | 3.73 | In utero losartan withdrawal and subsequent development of fetal inferior vena cava thrombosis. ( Bakkum, JN; Brost, BC; Johansen, KL; Johnston, BW; Watson, WJ, 2006) |
| "Losartan is an angiotensin II (Ang II) type I receptor (AT1R) antagonist proposed to have an antiplatelet activity via the inhibition of both the thromboxane A2 (TXA2) receptor (TP) and the glycoprotein VI (GPVI)." | 2.80 | Inhibition of Glycoprotein VI Clustering by Collagen as a Mechanism of Inhibiting Collagen-Induced Platelet Responses: The Example of Losartan. ( Jandrot-Perrus, M; Jiang, P; Jondeau, G; Loyau, S; Ropers, J; Tchitchinadze, M, 2015) |
| "Losartan is a non-peptidic inhibitor of AT1 receptors." | 2.41 | Angiotensin II AT(1) receptor antagonists and platelet activation. ( Casado, S; Gómez, J; Jiménez, A; Lopez-Bloya, A; López-Farré, A; Montón, M; Núñez, A; Rico, L; Sánchez de Miguel, L, 2001) |
| "Pathogenic thrombus formation accounts for the etiology of many serious conditions including myocardial infarction, stroke, deep vein thrombosis, and pulmonary embolism." | 1.56 | Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis. ( Foster, H; Foster, R; Philippou, H; Wilson, C, 2020) |
| "Losartan has been proposed to block clustering of GPVI but not to affect binding of collagen." | 1.56 | Comparison of the GPVI inhibitors losartan and honokiol. ( Eble, JA; Heemskerk, JWM; Nagy, M; Onselaer, MB; Pallini, C; Perrella, G; Pike, JA; Poulter, NS; Quintanilla, LG; Watson, SP, 2020) |
| "Stasis-induced venous thrombus was allowed to age for 7 hours before intravenous injection of EXP3174 (10 mg/kg and 30 mg/kg)." | 1.51 | Losartan metabolite EXP3174 reduces the weight of formed thrombus in 2K1C hypertensive rats. ( Chabielska, E; Gromotowicz-Poplawska, A; Nazarko-Sadowska, J, 2019) |
| "Losartan and captopril were able to recover the thrombus formation time without changing blood pressure, activated partial thromboplastin time (aPTT), PT (prothrombin time), platelet aggregation and adhesion, but decreased gelatinase activity." | 1.43 | Losartan and captopril treatment rescue normal thrombus formation in microfibril associated glycoprotein-1 (MAGP1) deficient mice. ( Antunes, E; Braga, GG; Costa, FTM; Dos Santos, L; Godoy, JA; Krieger, JE; Mendes, CB; Nery Diez, ACC; Pereira, DS; Vassequi-Silva, T; Vicente, CP; Werneck, CC, 2016) |
| "Overt proteinuria is a strong risk factor for thromboembolism, owing to changes in the levels of various coagulation proteins and urinary antithrombin loss." | 1.37 | The impact of antiproteinuric therapy on the prothrombotic state in patients with overt proteinuria. ( Kluin-Nelemans, HC; Laverman, GD; Mahmoodi, BK; Mulder, AB; Mulder, R; Navis, G; Slagman, MC; Spronk, HM; Ten Cate, H; Vogt, L; Waanders, F, 2011) |
| "Time to occlusive thrombus formation and weight of the thrombus were recorded." | 1.31 | Inhibition of arterial thrombogenesis by quinapril but not losartan. ( Bavry, AA; Li, D; Mehta, JL; Phillips, MI; Zander, DS, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Foster, H | 1 |
| Wilson, C | 1 |
| Philippou, H | 1 |
| Foster, R | 1 |
| Gromotowicz-Poplawska, A | 1 |
| Nazarko-Sadowska, J | 1 |
| Chabielska, E | 2 |
| Onselaer, MB | 1 |
| Nagy, M | 1 |
| Pallini, C | 1 |
| Pike, JA | 1 |
| Perrella, G | 1 |
| Quintanilla, LG | 1 |
| Eble, JA | 1 |
| Poulter, NS | 1 |
| Heemskerk, JWM | 1 |
| Watson, SP | 1 |
| Jiang, P | 1 |
| Loyau, S | 1 |
| Tchitchinadze, M | 1 |
| Ropers, J | 1 |
| Jondeau, G | 1 |
| Jandrot-Perrus, M | 1 |
| Vassequi-Silva, T | 1 |
| Pereira, DS | 1 |
| Nery Diez, ACC | 1 |
| Braga, GG | 1 |
| Godoy, JA | 1 |
| Mendes, CB | 1 |
| Dos Santos, L | 1 |
| Krieger, JE | 1 |
| Antunes, E | 1 |
| Costa, FTM | 1 |
| Vicente, CP | 1 |
| Werneck, CC | 1 |
| Kramkowski, K | 1 |
| Mogielnicki, A | 1 |
| Leszczynska, A | 1 |
| Buczko, W | 2 |
| Mahmoodi, BK | 1 |
| Mulder, AB | 1 |
| Waanders, F | 1 |
| Spronk, HM | 1 |
| Mulder, R | 1 |
| Slagman, MC | 1 |
| Vogt, L | 1 |
| Navis, G | 1 |
| Ten Cate, H | 1 |
| Kluin-Nelemans, HC | 1 |
| Laverman, GD | 1 |
| Murad, JP | 1 |
| Espinosa, EV | 1 |
| Ting, HJ | 1 |
| Khasawneh, FT | 1 |
| Petnehazy, T | 1 |
| Stokes, KY | 1 |
| Russell, JM | 1 |
| Granger, DN | 1 |
| Díez, J | 1 |
| Bakkum, JN | 1 |
| Brost, BC | 1 |
| Johansen, KL | 1 |
| Johnston, BW | 1 |
| Watson, WJ | 1 |
| Devereux, RB | 1 |
| Dahlöf, B | 1 |
| Grothusen, C | 1 |
| Umbreen, S | 1 |
| Konrad, I | 1 |
| Stellos, K | 1 |
| Schulz, C | 1 |
| Schmidt, B | 1 |
| Kremmer, E | 1 |
| Teebken, O | 1 |
| Massberg, S | 1 |
| Luchtefeld, M | 1 |
| Schieffer, B | 1 |
| Gawaz, M | 1 |
| Pawlak, R | 1 |
| Golatowski, J | 1 |
| Bavry, AA | 1 |
| Li, D | 1 |
| Zander, DS | 1 |
| Phillips, MI | 1 |
| Mehta, JL | 1 |
| López-Farré, A | 1 |
| Sánchez de Miguel, L | 1 |
| Montón, M | 1 |
| Jiménez, A | 1 |
| Lopez-Bloya, A | 1 |
| Gómez, J | 1 |
| Núñez, A | 1 |
| Rico, L | 1 |
| Casado, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Randomised, Double Blind Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome[NCT00763893] | Phase 3 | 303 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to A similar publication has been released, suggesting a beneficial effect of sartans, and only 15 patients remained to be seen for their visit at 36 months.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for losartan and Thrombosis
| Article | Year |
|---|---|
Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Endothelium, Vascular; Fibrosis; H | 2006 |
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2007 |
Angiotensin II AT(1) receptor antagonists and platelet activation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin Receptor Antagonists | 2001 |
1 trial available for losartan and Thrombosis
| Article | Year |
|---|---|
Inhibition of Glycoprotein VI Clustering by Collagen as a Mechanism of Inhibiting Collagen-Induced Platelet Responses: The Example of Losartan.
Topics: Adenosine Diphosphate; Animals; Blood Platelets; Collagen; Horses; Humans; Immobilized Proteins; Int | 2015 |
12 other studies available for losartan and Thrombosis
| Article | Year |
|---|---|
Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
Topics: Binding Sites; Biological Products; Humans; Ligands; Losartan; Molecular Dynamics Simulation; Platel | 2020 |
Losartan metabolite EXP3174 reduces the weight of formed thrombus in 2K1C hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Coagulation; Blood Platelets; Blood Pressure; Hemostasis; Hy | 2019 |
Comparison of the GPVI inhibitors losartan and honokiol.
Topics: Biphenyl Compounds; Blood Platelets; Collagen; Humans; Lectins, C-Type; Lignans; Losartan; Membrane | 2020 |
Losartan and captopril treatment rescue normal thrombus formation in microfibril associated glycoprotein-1 (MAGP1) deficient mice.
Topics: Animals; Antihypertensive Agents; Captopril; Carotid Arteries; Contractile Proteins; Extracellular M | 2016 |
Angiotensin-(1-9), the product of angiotensin I conversion in platelets, enhances arterial thrombosis in rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arteries; Blood Pla | 2010 |
The impact of antiproteinuric therapy on the prothrombotic state in patients with overt proteinuria.
Topics: Adult; Double-Blind Method; Female; Humans; Losartan; Male; Middle Aged; Placebos; Proteinuria; Prot | 2011 |
Characterization of the in vivo antiplatelet activity of the antihypertensive agent losartan.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Animals; | 2012 |
Angiotensin II type-1 receptor antagonism attenuates the inflammatory and thrombogenic responses to hypercholesterolemia in venules.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Platelets; Cell Movement; Endothelium, Vascu | 2005 |
In utero losartan withdrawal and subsequent development of fetal inferior vena cava thrombosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Contraindications; Diabetes Mellitus, Type 2; Female; Fetal | 2006 |
EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on atherothrombosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Flow Cytometry; Humans; Losartan; Microsco | 2007 |
The antithrombotic effect of captopril and losartan on experimental arterial thrombosis in rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1998 |
Inhibition of arterial thrombogenesis by quinapril but not losartan.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Dose-Response Rel | 2000 |